Abstract
The investigation about hereditary breast and ovarian cancer（HBOC）in Japan already lags far behind in the Western country or Asia. However, by verifying the data in detail, starting behind time can realize it as an advantage conversely from the viewpoint of efficiency. And it is a fact that problems that should be solved are also visible to pinpoint. In the Western country, MRI screening is already recommended to the high-risk women. When it has recognized that verification of the usefulness of the MRI screening for BRCA1 and BRCA2 career patients（high-risk women）is indispensable also in Japan, it is necessary to examine the possibility of adding new diagnostic imaging technology other than MRI. Furthermore, the education of MRI-guided biopsy and the interpretation method of breast MRI are also indispensable.
